- Home
- ZVRA vs CELC Comparison
ZVRA vs CELC Comparison
Compare ZVRA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- CELC
- Stock Information
- Founded
- ZVRA 2006
- CELC 2011
- Country
- ZVRA United States
- CELC United States
- Employees
- ZVRA N/A
- CELC N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- CELC Medical Specialities
- Sector
- ZVRA Health Care
- CELC Health Care
- Exchange
- ZVRA Nasdaq
- CELC Nasdaq
- Market Cap
- ZVRA 400.8M
- CELC 440.0M
- IPO Year
- ZVRA 2015
- CELC 2017
- Fundamental
- Price
- ZVRA $9.07
- CELC $11.60
- Analyst Decision
- ZVRA Strong Buy
- CELC Strong Buy
- Analyst Count
- ZVRA 8
- CELC 5
- Target Price
- ZVRA $22.29
- CELC $30.80
- AVG Volume (30 Days)
- ZVRA 551.0K
- CELC 140.7K
- Earning Date
- ZVRA 08-12-2025
- CELC 08-13-2025
- Dividend Yield
- ZVRA N/A
- CELC N/A
- EPS Growth
- ZVRA N/A
- CELC N/A
- EPS
- ZVRA N/A
- CELC N/A
- Revenue
- ZVRA $40,588,000.00
- CELC N/A
- Revenue This Year
- ZVRA $292.31
- CELC N/A
- Revenue Next Year
- ZVRA $78.65
- CELC N/A
- P/E Ratio
- ZVRA N/A
- CELC N/A
- Revenue Growth
- ZVRA 46.47
- CELC N/A
- 52 Week Low
- ZVRA $4.20
- CELC $7.58
- 52 Week High
- ZVRA $9.76
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- ZVRA 58.37
- CELC 49.88
- Support Level
- ZVRA $8.71
- CELC $11.85
- Resistance Level
- ZVRA $9.37
- CELC $13.40
- Average True Range (ATR)
- ZVRA 0.33
- CELC 0.70
- MACD
- ZVRA -0.05
- CELC -0.09
- Stochastic Oscillator
- ZVRA 50.93
- CELC 35.83
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.